Group founder’s elder son raises $341 million from selling part of his stake in retail flagship, marking his withdrawal from a bitter years-long power struggle with his brother.
The Henan-based operator of private schools aims for a conservative valuation despite market recovery.
Falling interest rates should be good news for India's prospective new asset class — infrastructure investment trusts — as long as issuers price the first few deals to perform.
PCCW offloads HKT Trust stake in Hong Kong’s first billion-dollar block trade in 10 months. That points at a likely revival in Hong Kong's slumbering equities market.
The US tech giant’s sale of non-voting shares offers an opportunity for Hong Kong to rethink its approach to new listings. It's an option the city should reject.
The Henan-based private school operator plans to list in Hong Kong, following Wisdom Education’s debut late last month.
Thai warehouse operator enters final preparation for a domestic IPO of its water treatment business as it seeks capital to reduce leverage after Hemaraj deal.
Vodafone is unlikely to proceed with the planned flotation of its Indian unit after entering negotiations to sell the assets to Idea Cellular.
Asia’s oldest exchange moves ahead with its listing plan, a move seen as crucial as India creates a developed equities market. NSE could be next.
Memory chip maker pulls off one of the biggest convertible bond sales in Taiwanese history, reaping $500 million in Asia ex-Japan's first international convertible of 2017.
Southern China's largest private school operator sets Hong Kong IPO despite uncertainty over China's educational structure and future tax structure.
Pricing of Chinese paediatric hospital operator's deal indicates 2017 could again see sheer weight of onshore demand keep IPO valuations above levels offshore investors believe the fundamentals warrant.
The online game developer looks en route to a backdoor listing in Shenzhen as a tussle between shareholders comes to an end.
Sentiment towards the S-reit sector has been improving. But is it just a dead cat bounce?
Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.